<![CDATA[Venetoclax/HMA Combo Demonstrates Real-World Efficacy in Unfit AML]]>

Data ReadoutpositiveVenetoclaxHypomethylating agentPositive

AI Analysis

Summary

Real-world data demonstrates venetoclax combined with a hypomethylating agent achieved a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia patients deemed unfit for intensive treatment.

Clinical Trial Data

Outcome Details

Real-world median overall survival of 13.0 months in newly diagnosed unfit AML patients

Importance:5/10

Sentiment:

0.60

oncologyacute myeloid leukemiareal-world evidencevenetoclaxhypomethylating agent

Related Companies

$ALMDT.PA

Read the original article

Published by Cancer Network on August 26, 2026 2:00 PM

Read Original